|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV PatientsSeptember 12th 2025
Latest NIMBLE Study Results Highlight Progress in gMG ResearchSeptember 12th 2025
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug TrialsSeptember 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
3
Latest NIMBLE Study Results Highlight Progress in gMG Research
4
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
